Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme

Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme

Objective To assess the appropriateness of expanded serological activity eligibility criteria for belimumab use in the UK systemic lupus erythematosus (SLE) population (and possibly other countries), which includes patients with either anti-double-stranded DNA (anti-dsDNA) positivity or hypocompleme...

Full description

Saved in:
Bibliographic Details
Main Authors: Ian N Bruce, Damon L Bass, David A Roth, Toni Maslen, David D'Cruz, Mihaela Ianosev, Christel Wilkinson
Format: Article
Language:English
Published: BMJ Publishing Group 2021-04-01
Series:Lupus Science and Medicine
Online Access:https://lupus.bmj.com/content/8/1/e000459.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items